Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here Staff

Dr. Lucy Norris
SENIOR EXP OFFICER OBS&GYN (P/T 17/8/06), Obstetrics

Biography

Lucy Norris MSc Mol. Med. PhD https://www.researchgate.net/profile/Lucy_Norris) Lucy Norris graduated from Trinity College Dublin with an honours degree in Biochemistry. She was awarded a PhD in 1992 from TCD Dept of Obstetrics and Gynaecology based on her work investigating platelet activation in pregnancy, pre-eclampsia and oral contraception. She is the Principal Investigator of Coagulation Research group at the Department of obstetrics and Gynaecology and has over 25 years' experience in the area of haemostasis and thrombosis research. Her current research program focuses on the prediction of venous thrombosis in gynaecological cancer and the role of coagulation gene expression in the aetiology of ovarian cancer funded by the HRB. She has over 60 peer reviewed publications, many as senior author, including 5 invited reviews. She is a founder member of INNOVATION the Irish National Network for Ovarian Cancer Collaboration which was established with a mission to integrate patient clinical pathways with cutting edge research to improve diagnosis and treatment of ovarian cancer. (http://www.molecularmedicineireland.ie/research/innovation/). She is a member of the editorial board for the journal 'Thrombosis Research' and co-editor in chief of the journal "Thrombosis Update".

Publications and Further Research Outputs

Peer-Reviewed Publications

Eilis Perez, Bashir Mohamed, Danny Di Capua, Noreen Gleeson, Claire Thompson, Feras Abu Saadeh, Cara Martin, Lucy Norris, Ciaran O'Riain, Mark Bates, Lorraine O'Driscoll, John O'Leary, Sharon O'Toole. , High Expression Of Neuromedin U In High Grade Serous Ovarian Cancer Confers A Progression Free Survival Advantage., Laboratory Investigation, 99, 2019, pp101 - 101 Published Abstract, 2019

B Mohamed, S O'Toole, S Elbaruni, L Norris, F AbuSaadeh, S Gray, J. O'Leary , EP926 PAD enzymes as a candidate therapeutic target in ovarian cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA497 - A497 Published Abstract, 2019

S O'Toole, M Foley, S Rizmee, L Norris, W Kamran, N Ibrahim, M Ward, C Thompson, C Murphy, M Anglim, T D'Arcy, N Farah, H O'Connor, J O'Leary, F AbuSaadeh, N Gleeson, HE4 has a role in identifying high risk prognostic factors in endometrial cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA351 - A352 Published Abstract, 2019

O'Toole S, Melarcode H, Elbaruni S, F AbuSaadeh, M Ward, M Gallagher, L Norris, S Gray, J O`Leary and B Mohamed., EP926 PAD enzymes as a candidate therapeutic target in ovarian cancer, International Journal of Gynaecological Cancer, 29, ((Supplement 4)), 2019, ppA497 - A497 Published Abstract, 2019

Marchocki Z, Norris L, O'Toole S, Gleeson N, Abu Saadeh F, Patients' experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynaecological cancer. A prospective observational study, International Journal of Gynaecological Cancer. , 2019 Journal Article, 2019 DOI

Marchocki Z, Norris LA, , Abu Saadeh F, Gleeson N, Recurrence of Venous thromboembolism in gynaecological malignancies, incidence, risk factors and impact on survival, European Journal of Gynae Oncology , 40, (3), 2019, p413 - 419 Journal Article, 2019 DOI

Melad Saed, Sharon O'Toole, Lucy Norris, Steven Gray, Feras Abu Saadeh, John O'Leary, Bashir Mohamed. , The Efficacy Of Nanocomplexes Complexed With Specific Biomarker Targets In Ovarian Cancer Treatment, An Ex-Vivo Explant Case Study, Laboratory Investigation, 99, 2019, pp106 - 106 Published Abstract, 2019

Z. Marchocki, N. Gleeson, F. Abu Saadeh, M.P. Ward, S.A. O'Toole, L.A. Norris, Fibrinogen, D-Dimers and thrombin generation assays as predictors of the risk of recurrent VTE in patients with gynaecological malignancies, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), 2018, pp200 - 200 Published Abstract, 2018 DOI

LA Norris, F Abu Saadeh, M Ward, SA O'Toole, Z Marchocki, N. Ibrahim, N Gleeson, Development and validation of a risk model for prediction of venous thromboembolism in gynaecological cancer patients, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), Elsevier, 2018, ppS183 - S184 Oral Presentation, 2018 DOI

Thompson C, Kamran W, Dockrell L, Khalid S, Kumari M, Ibrahim N, OʼLeary J, Norris L, Petzold M, OʼToole S, Gleeson N, The Clearance of Serum Human Epididymis Protein 4 Following Primary Cytoreductive Surgery for Ovarian Carcinoma, International Journal of Gynaecological Cancer, 28, (6), 2018, p1066 - 1072 Journal Article, 2018 DOI

Z. Marchocki, L.N. Norris, S.A. O'Toole, N. Gleeson, F. Abu Saadeh S235, Patients experience and compliance with extended LMWH prophylaxis post-surgery for gynaecological cancer, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2018, 164, (Supplement 1), Elsevier, 2018, ppS235 - S235 Published Abstract, 2018 DOI

Thompson C, McCormick C, Kamran W, O'Riain C, Norris L, Gallagher D, Gleeson N., Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes, Irish Journal of Medical Science, 2018 Journal Article, 2018 DOI

Ward MP, Abu Saadeh, F, O'Toole S, Marchocki Z, Gleeson N, Norris LA, Optimisation of Thrombin Generation as a Predictive Biomarker for Venous Thromboembolism in Gynaecological Malignancies, Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis, Dublin, July 2018, 2, (Supplement 1), Wiley, 2018, ppPB518 - PB518 Published Abstract, 2018 DOI

C. Spourquet, M.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris., Expression of Coagulation Proteases from the Activated Protein C Pathway in Ovarian Tumours, Research Practice in Thrombosis and Haemostasis , ISTH, Berlin, July 2017, 1, (1), Wiley, 2017, pp630 - 630 Published Abstract, 2017 DOI

Marchocki Z, Abu Saadeh F, Gleeson N, Norris L, Risk of recurrence of venous thromboembolism in patients with gynaecological cancer, Thrombosis Research, Womens Issues in Thrombosis and Haemostasis, Barcelona, March 2017, 151, (Supplement 1), 2017, ppS133 - S133 Published Abstract, 2017 DOI

Abu Saadeh, F, Langhe R, Galvin DM, O Toole SA, O'Donnell DM, Gleeson N, Norris LA, Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. , Thrombosis Research, 139, 2016, p135 - 141 Journal Article, 2016 DOI

Martin F, Long JC, O'Toole SA, O'Leary JJ, Abu Saadeh F, Gleeson N, Norris LA, Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?, Thrombosis Research, International Congress on Thrombosis and Haemostasis Issues in Cancer, Bergamo, April 2016, 140, (Supplement 1), 2016, ppS181 - S181 Published Abstract, 2016 DOI

Petch S, Norris L, O'Toole S, Gleeson N, Abu Saadeh F., Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice, Thrombosis Research, 145, 2016, p126 - 128 Journal Article, 2016 DOI

Petch S, Norris LA, O'Toole SA, Gleeson N, Saadeh FA, OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice., 2016 Journal Article, 2016

Norris LA, Martin FA, O'Toole SA, Saadeh FA, Gleeson N, PO-24 - Determinants of thrombin generation in gynaecological malignancies., 2016 Published Abstract, 2016 DOI

Siti K. Ismail, Lucy Norris, Ali Khashan, Nigel Simpson, Gustaaf Dekker, Jenny Myers, Lesley McCowan, Louise Kenny, John R. Higgins, [174-POS], Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 5, (1), 2015, p89--90 Journal Article, 2015

Ismail SK, Norris L, Higgins JR, Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis, British Journal of Haematology, 2015, pdoi: 10.1111/bjh.13521. Journal Article, 2015 URL

Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S, A novel serum microRNA panel to discriminate benign from malignant ovarian disease, Cancer Letters, 356, ((2ptB)), 2015, p628-636- Journal Article, 2015 DOI

Abu Saadeh F, O'Toole S, Gleeson N, Norris L, Peak ant-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post surgery, Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer, , Bergamot Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014 Published Abstract, 2014

Kelly LA, Seidlova-Wuttke D, Wuttke W, O'Leary JJ, Norris LA, Estrogen receptor alpha augments changes in hemostatic gene expression in HepG2 cells treated with estradiol and phytoestrogens. , Phytomedicine , 21, (2), 2014, p155 - 158 Journal Article, 2014 URL

Ibrahim N, Norris L, Nikolov N, Gleeson N, Thromboelastography as a tool for detecting hypercoagulability in gynaecological cancer patients undergoing surgery, Thrombosis Research, 7th International Conference on Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014 Published Abstract, 2014

Ibrahim N, Norris L, O'Toole S, Gleeson N, The effect of LMWH (tinzaparin) post surgery in gynaecological patients: a study of ant-Xa activity levels., Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, pps204- Published Abstract, 2014

Ismail SK, Norris L, O'Shea S, Higgins JR, Weight-adjusted LMWH Prophylaxis Provides More Effective Thrombin Inhibition in Morbidly Obese Pregnant Women, Thrombosis Research, 134, (2), 2014, p234 - 239 Journal Article, 2014 DOI

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 Journal Article, 2013 DOI TARA - Full Text

Abu Saadeh, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N, Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk., Thrombosis Research, 132, 2013, p627 - 634 Journal Article, 2013 DOI

Brosnan JF, Sheppard BL, Kelly LA, O'Leary JJ, Norris LA, Norethisterone acetate alters coagulation gene expression in vitro in human cell culture., Thrombosis research, 131, (1), 2013, p72 - 77 Journal Article, 2013 DOI

Abu Saadeh F, Norris L, O'Toole S, Gleeson N, Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival., European Journal of Obstetrics & Gynecology and Reproductive Biology , 170, (1), 2013, p214 - 218 Journal Article, 2013 Other

Abu Saadeh F, Norris L, O'Toole S, Langhe R, O'Leary JJ, Gleeson N., Does tissue factor and tissue factor pathway inhibitor over-expression play a role in the development of venous thromboembolism in ovarian cancer patients?, Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, ((Suppl 1)), Elsevier, 2012, pp170- Published Abstract, 2012 URL

Abu Saadeh F, Norris L, O'Toole S, Langhe R, Gleeson N., Procoagulant activity in patients with gynecological malignancies and the effect of neoadjuvant chemotherapy , Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, (Suppl 1), Elsevier, 2012 Published Abstract, 2012 URL

Ismail SK, Norris L, Muttukrishna S, Higgins JR, Thrombin generation post elective caesarean section: Effect of low molecular weight heparin., Thrombosis research, 130, (5), 2012, p799 - 803 Journal Article, 2012 DOI

Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, O' Leary. J, Gleeson. N. , Why is venous thromboembolism is a common complication of ovarian cancer? , International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society. , Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE247- Published Abstract, 2012

Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N., ETP as a marker for venous thromboembolism in gynaecologial cancer patients post surgery, International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE249- Published Abstract, 2012

Abu Saadeh. F, Norris. L, O' Toole, Gleeson. N., Assessing the risk and mortality of venous thromboembolism in ovarian cancer., International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, ppE246- Meeting Abstract, 2012

Lynne Kelly, Shanthi Muttukrishna, Lucy Norris, John Higgins, P10. Placental expression of haemostatic and angiogenic markers in preeclampsia, Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 1, (3-4), 2011, p277 Journal Article, 2011

Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducrée J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O'Leary J, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011 Journal Article, 2011 TARA - Full Text

Kelly LA, O'Leary JJ, Seidlova-Wuttke D, Wuttke W, Norris LA, Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens, Thrombosis and Haemostasis, 104, (6), 2010, p1083-1289 Journal Article, 2010 TARA - Full Text

Hellgren M, Conard J, Norris L, Kluft C, Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone, Maturitas, 62, 2009, p287 - 293 Journal Article, 2009 DOI

Lucy A. Norris, Jeanette Brosnan, John Bonnar, Jacqueline Conard, Cornelius Kluft, Margareta Hellgren, Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone, Thromb Haemost, 2008 Journal Article, 2008

Thrombosis Research, (2008), Marc Rodger, Henri Versteeg, [Editorial board member] Journal, 2008

Norris L A, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M , INHIBITORS AND ACTIVATION MARKERS OF THE HAEMOSTATIC SYSTEM DURING HORMONE THERAPY: , Thrombosis and Haemostasis, 100, (2), 2008, p253 - 260 Journal Article, 2008

Brosnan JF, Sheppard BL, Norris LA, Haemostatic activation in post menopausal women taking low dose hormone therapy: less effect with transdermal administration?, Thrombosis and Haemostasis, 97, (4), 2007, p558 - 565 Journal Article, 2007 DOI

Yoneda M, Brosnan JF, Norris LA, Bonnar J, The effect of LMWH (Tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis, Thrombosis Research, 117, 2006, p283 - 290 Journal Article, 2006

Norris LA, Weldon S, Nugent A & Roche HM , LPS induced tissue factor expression in the THP-1 monocyte cell line is attenuated by conjugated linoleic acid, Thrombosis Research, 117, 2006, p475 - 480 Journal Article, 2006

Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J, Tinzaparin sodium for thrombosis treatment and prevention during pregnancy., American Journal of Obstetrics and Gynaecology, 190, (4), 2004, p495 - 501 Journal Article, 2004

Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G, Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study, Thrombosis and Haemostasis, 92, (4), 2004, p791 - 796 Journal Article, 2004

Oral Contraceptive and Hemostasis Study Group, The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large multicentre study, Contraception, 67, (3), 2003, p173 - 185 Journal Article, 2003

Out, H.J., Jespersen, J., Pabinger, I., MacRae, K., Crosignani, P., Skouby, S.O., Winkler, U.H., Norris, L., Gaspard, U., David, Van Enk, A., Van De Ende, A., Mishell, D., Voncken, D., Klipping, C., Sidelmann, J., The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomized multicenter study, Contraception, 67, (3), 2003, p173-185 Journal Article, 2003

Skouby, S.O., Jespersen, J., Kluft, C., Lowe, G.D.O., Norris, L., Stevenson, J., Samsioe, G., The European Consensus Development Conference 2002: Sex steroids and cardiovascular diseases: On the route to combined evidence from OC and HRT/ERT, Maturitas, 44, (1), 2003, p69-82 Journal Article, 2003

Norris, Blood Coagulation (invited review), Best Practice Research in Clinical Obstetrics and Gynaecol, 17, (3), 2003, p369 - 383 Journal Article, 2003

Skouby SO, Jespersen J, Kluft C, Lowe GD, Norris L Samsoie G, Stevenson J. Writing group for the 3rd European Conference on Sex Steroids and Cardiovascular disease, On the route to combined evidence from OC and HRT/ERT, European Journal of Contraceptive Reproductive Health Care, 7, (4), 2002, p185 - 198 Journal Article, 2002

Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J., Haemostatic risk factors in healthy post menopausal women taking hormone replacement therapy, Maturitas, 43, (2), 2002, p125 - 133 Journal Article, 2002

Skouby, S.O., Jespersen, J., Kluft, C., Lowe, G.D.O., Norris, L., Samsioe, G., Stevenson, J., On the route to combined evidence from OC and HRT/ERT, European Journal of Contraception and Reproductive Health Care, 7, (4), 2002, p185-198 Journal Article, 2002

Higgins JR, Bonnar J, Norris LA, Darling MR, Walshe JJ, The effect of pre-eclampsia on coagulation and fibrinolytic activation in the neonate, Thrombosis Research, 99, (6), 2000, p567 - 570 Journal Article, 2000

John R Higgins, John Bonnar, Lucy A Norris, Michael R.N Darling, Joseph J Walshe, The Effect of Pre-eclampsia on Coagulation and Fibrinolytic Activation in the Neonate, Thrombosis Research, 99, (6), 2000, p567--570 Journal Article, 2000

Winkler, U.H., Norris, L., Gaspard, U., Van Enk, A., Mishell, D., Voncken, D., Klipping, C., An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables: Outline of the protocol, Contraception, 59, (6), 1999, p345-355 Journal Article, 1999

Wen Y, Doyle MC, Norris LA, Sinnot, MM, Cooke T, Harrison RF, Feely J, Combined oestrogen-progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in post menopausal women, British Journal of Clinical Pharmacol, 47, (3), 1999, p315 - 321 Journal Article, 1999

Wen Y, Killalea S, Norris LA, Cooke T, Feely J, Vitamin E suplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation, European Journal of Clinical Investigation, 29, (12), 1999, p1027 - 1034 Journal Article, 1999

Bonnar J, Green R, Norris L, Perinatal aspects of inherited thrombophilia, Seminars in Thrombosis and Haemostasis, 25, (5), 1999, p481 - 485 Journal Article, 1999

The Oral Contraceptive and Hemostasis Study Group, An open label randomised study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables, Contraception, 59, 1999, p345 - 355 Journal Article, 1999

Norris LA, Nitric Oxide in the Uteroplacental, fetoplacental and peripheral circulations in pre-eclampsia, Obstetrics and Gynaecology, 93, (6), 1999, p958 - 963 Journal Article, 1999

Bonnar J, Norris LA, Green R, Low molecular weight heparin for thromboprophylaxis during caesarean section, Thrombosis Research, 96, (4), 1999, p317 - 322 Journal Article, 1999

Adebayo GI, Norris L, Devitt M, Bonnar J, Feely J, Effects of oral contraceptive containing different progestogens on sodium lithium countertransport in normal females, Journal of Human Hypertension, 12, (4), 1998, p235 - 238 Journal Article, 1998

Comparative assessment of haemostatic variables with focus on levonorgestrel in, editor(s)Teichman AT, Corbin A , Levonorgestrel, Berlin, George Theime Verlag, 1998, pp39 - 46, [Bonnar J, Norris LA, Sheppard BL] Book Chapter, 1998

Bonnar J, Green R, Norris L, Inherited thrombophilia and pregnancy: the obstetric perspective, Seminars in Thrombosis and Haemostasis, 24, (Suppl (1)), 1998, p49 - 53 Journal Article, 1998

Higgins JR, Walshe JJ, Darling MR, Norris L, Bonnar J, Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies, American Journal of Obstetrics and Gynaecology, 179, (2), 1998, p520 - 526 Journal Article, 1998

Lucy A. Norris, John Bonnar, 9 Haemostatic changes and the oral contraceptive pill, Baillière's Clinical Obstetrics and Gynaecology, 11, (3), 1997, p545--564 Journal Article, 1997

Norris LA, Bonnar J, Haemostatic changes and the oral contaceptive pill, Ballieres Clinics in Obstetrics and Gynaecology, 11, (3), 1997, p545 - 564 Journal Article, 1997

Wu JJ, Yakoob J, Norris LA, Keeling PW, Is the fertile period reduced in patients with inflammatory bowel disease, Irish Journal of Medical Science, 165, (1), 1996, p35 - 36 Journal Article, 1996

Wu, J.J., Yakoob, J., Norris, L.A., Keeling, P.W.N., Is the fertile period reduced in patients with inflammatory bowel disease? Short report, Irish Journal of Medical Science, 165, (1), 1996, p35-36 Journal Article, 1996

Norris LA, Bonnar J, The effect of oestrogen dose and progestogen type on haemostatic changes in women taking oral contraceptives, British Journal of Obstetrics and Gynaecology, 103, (3), 1996, p261 - 267 Journal Article, 1996

Wu J, Norris LA, Wen JC, Sheppard BL, Feely J, Bonnar J, The effect of hormone replacement therapy on plasma vitamin E levels in post menopausal women, European Journal of Obstetrics Gynaecology and reproductive biology, 66, (2), 1996, p151 - 154 Journal Article, 1996

Norris LA, Devitt M, Bonnar J, The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users, Thrombosis research, 81, (4), 1996, p407 - 417 Journal Article, 1996

Norris LA, Bonnar J, Increased whole blood aggregation in oral contraceptive users can be prevented in vitro by a thromboxane sythetase inhibitor, Gynecological Endocrinology, 10, (Supplement 2), 1996, p119 - 121 Journal Article, 1996

Norris LA, Bonnar J, Estrogen dose and progestogen type: their effect on hemostatic changes in oral contraceptive users, Gynecological Endocrinolgy, 10, (Supplement 2), 1996, p119 - 121 Journal Article, 1996

Bloemenkamp K, Hannaford P, Helmerhorst F, Jespersen J, Kluft C, Norris L, Skouby S (Writing Group) , Consensus statement: Combined oral contraceptives and cardiovascular disease, Gynecological Endocrinology, 10 , (Supplement 2), 1996, p119 - 121 Journal Article, 1996

Norris LA, Bonnar J, New low dose oral contraceptives: less thrombotic risk, Modern medicine, 25, (9), 1995, p27 - 30 Journal Article, 1995

Norris LA, Bonnar J, New low dose oral contraceptives: less thrombotic risk?, Modern medicine, 25, (9), 1995, p27 - 30 Journal Article, 1995

Norris LA, Sex steroids and changes in the cardiovascular system I: Change in systems relevant to the development of cardiovascular disease- Annotation of Esbjerg I consensus meeting., Combined oral contraceptives and cardiovascular disease: Consensus Development meeting, Amsterdam , November , 1995, Published in Gynecological Endocrinology 1996;10: 25-27 Invited Talk, 1995

Norris LA, Sheppard BL, Burke G, Bonnar J, Platelet activation in normotensive and hypertensive pregnancies complicated by intra-uterine growth retardation, British Journal of Obstetrics and Gynaecology, 101, (3), 1994, p209 - 214 Journal Article, 1994

Norris LA, Bonnar J, The in vitro effect of aspirin on increased whole blood platelet aggregation in oral contraceptive users, Thrombosis Research, 74, (1), 1994, p309 - 315 Journal Article, 1994

Norris LA, Bonnar J, Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives, Thrombosis and Haemostasis, 72, (6), 1994, p926 - 930 Journal Article, 1994

Norris LA, Gleeson N, Sheppard BL, Bonnar J, Whole blood platelet aggregation in moderate and severe pre-eclampsia, British Journal of Obstetrics and Gynaecology, 100, (7), 1993, p684 - 688 Journal Article, 1993

Norris LA, Platelet activation in pregnancy and oral contraception, Trinity College Dublin, 1992 Thesis, 1992

Norris LA, Sheppard BL, Bonnar J, Increased whole blood platelet aggregation in normal pregnancy can be prevented in vitro by aspirin and dazmegerel (UK38485), British Journal of Obstetrics and Gynaecology, 99, (3), 1992, p253 - 257 Journal Article, 1992

Non-Peer-Reviewed Publications

M.P. Ward, F.A. Saadeh, J.J. O'Leary, N. Gleeson, S.A. O'Toole, L.A. Norris ., The Effect of Neoadjuvant Chemotherapy on the Activated Protein C (aPC) Pathway in High Grade Serous Ovarian Cancer Patients., Research Practice in Thrombosis and Haemostasis, International Society for Thrombosis and Haemostasis , Berlin, July 2017, 1, (1), Wiley, 2017, pp625 - 625 Published Abstract, 2017 DOI

Lucy Norris, Can we predict VTE in gynaecological cancer?, Irish Society for Gynae-Oncology (ISGO) annual scientific meeting 'TRANSLATION AND INNOVATION'., Dublin, December 1st , 2016, ISGO Invited Talk, 2016

Lucy Norris, Prediction and Prevention of venous thromboembolism in Gynaecological cancer. , Master class in Cancer and Thrombosis, Dublin, July 7, 2015, 87- Invited Talk, 2015

Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014 Published Abstract, 2014

Abu Saadeh F, Norris L, O'Toole S, Gleeson N. , The role of tissue factor and tissue factor pathway inhibitor in ovarian cancer, Thrombosis Research, Womens Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl 3), Elsevier, 2011, pp149 - 149 Meeting Abstract, 2011

Lynne Kelly, Shanthi Muttukrishna, Lucy Norris, John Higgins, Placental expression of haemostatic and angiogenic markers in preeclampsia, Hydrometallurgy, 1, (3), 2011, pp277- Published Abstract, 2011

SK Ismail, Norris LA, Muttukrishna S, Higgins JR, Effect of LMWH prophylaxis on thrombin generation post caesarean section, Thrombosis Research, Women's Health Issues in Thrombosis and Haemostasis, Berlin, February 2011, 127, (Suppl), 2011, ppS137 - S137 Meeting Abstract, 2011

Lucy Norris, HRT and haemostasis, UCC Obstetrics and Gynaecology, research seminar, Cork, February, 2011, UCC, 87- Invited Talk, 2011

Lucy Norris, Hormones and the risk of thrombosis., Update on Coagulation, Dublin, March, 2010, National Centre for Coagulation and Hereditary disorders, 87- Invited Talk, 2010

Kelly L, O'Leary J, Wuttke W, Norris L. , Effects of Genistein versus Oestrogen on haemostatic gene expression in ovariectomised rats, Journal of Thrombosis and Haemostasis , International Society for Thrombosis and Haemostasis, Boston, July 2009, 7 , (Supplement 2), 2009, ppPP-WE-3731- Meeting Abstract, 2009

Brosnan J, Sheppard BL, Norris LA, Differential effects of transdermal and oral estradiol/norethisterone acetate hormone therapies on coagulation and fibrinolytic markers, Journal of Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis, Geneva, July 2007, 5, (Suppl 2), 2007, pp0-S-050 - 0-S-050 Meeting Abstract, 2007

Brosnan J Sheppard, BL, Norris LA, Sex steroids used in hormone treatment alter coagulation gene expression, Journal of Thrombosis and Haemostasis, International society on thrombosis and haemostasis, Geneva, 2007, 5, (Suppl. 2), 2007, ppP-S-626- Meeting Abstract, 2007

Brosnan JF, Norris LA, Sheppard BL, Effects of the menopause on circulating adhesion molecules, 2001, pp360- Meeting Abstract, 2001

Norris LA, Bonnar J, Platelet activation in oral contraceptive users may be prevented in vitro by low dose aspirin, Irish Journal of Medical Science, (Supplement II), 1993 Meeting Abstract, 1993

Norris LA, Devitt M, Bonnar J, Fibrinolytic activation and inhibition in women using new low dose oral contraceptives, Fibrinolysis, 6, (Supplement 2), 1992 Meeting Abstract, 1992

Norris LA, Sheppard BL, Bonnar J, Whole blood platelet activation in normal pregnancy, Irish Journal of Medical Science, 160, 1990, pp358- Meeting Abstract, 1990

Norris LA, Carroll ME, Bonnar J, In vitro aspirin inhibition of platelet activation in oral contraceptive users and controls, Irish Journal of Medical Science, 159, 1989, pp98- Meeting Abstract, 1989

Daly L, Norris LA, Carroll ME, Bonnar J, Effects of new oral contraceptives containing gestodene and desogestrel on fibrinolysis, Fibrinolysis, 1, 1988, pp161- Meeting Abstract, 1988

Norris LA, Carroll ME, Bonnar J, Effect of triphasic oral contraceptives on whole blood platelet aggregation, Irish Journal of Medical Science , 157, 1988 Meeting Abstract, 1988

Research Expertise

Description

The role of coagulation proteases and platelets in the aetiology of gynaecological cancers. Development of risk models for the prediction of thrombosis in gynaecological cancer patients. Aetiology of thrombosis risk in high risk pregnancy patients. Effects of oestrogens, progestogens and phytoestogens on coagulation gene expression and their role in thrombosis risk. The role of coagulation gene expression in the transition from endometriosis to clear cell cancer.

Projects

  • Title
    • A risk model for prediction of venous thromboembolism in gynaecological cancer patients post surgery
  • Summary
    • Venous thromboembolism (VTE) is a common cause of death in patients with solid tumours. Cancer itself causes a hypercoagulable state, in addition chemotherapy and surgery enhance the risk. Gynaecological cancers have been associated with high rates of VTE which is excacerbated by pelvic surgery and chemotherapy. A recent study in our centre showed that one third of VTE in ovarian cancer patients occurs within 5 days of surgery despite heparin prophylaxis. Recently, clinical risk models have been developed to predict VTE in patients undergoing chemotherapy, these models have been shown to be more powerful when combined with haemostatic biomarkers. Thrombus formation is complex in cancer and is thought to result from a release of procoagulant material from the tumour combined with damage to the endothelium as a result of chemotherapy and surgery. Global tests of hypercoagulability which capture these effects are therefore attractive as determinants of thrombotic risk. Calibrated automated thrombograpy (CAT) is a recently developed global test which measures thrombin generation in plasma. Increased thrombin generation is predictive of VTE in a variety of clinical settings. The overarching aim of this project is to develop and validate a specific risk scoring model for VTE risk in gynaecological cancer patients using a combination of easily available clinical and laboratory parameters and haemostatic biomarkers. In a large population of gynaecological cancer patients, we will identify the key risk factors for VTE and use them to derive a risk score model. Based on our pilot data, we believe that a thrombin generation test may be a useful biomarker for VTE in gynaecological cancer. By understanding the mechanisms by which gynaecological cancer increases procoagulant activity, we will optimise a specific thrombin generation assay which when combined with the derived risk score model will accurately identify gynaecological cancer patients at high risk of VTE.
  • Funding Agency
    • HRB
  • Date From
    • 2013
  • Date To
    • 2017
  • Title
    • Towards increased awareness and understanding of the risk of thrombosis in gynaecological cancers
  • Summary
    • A recent survey of patients who suffered a thrombosis during their cancer journey showed that, generally, patients are not warned about the risk of clots during cancer and are not told what to look out for. In addition research by our group has shown that only 45% of gynaecologists in Europe are using the correct guidelines for thrombosis prevention. The aim of this project is to increase awareness among patients regarding thrombosis and to provide an opportunity for knowledge exchange between gynaecologist and scientists working in the area
  • Funding Agency
    • HRB
  • Date From
    • January 2016
  • Date To
    • March 2017
  • Title
    • Interrogation of the Onco-metabolome in ovarian cancer
  • Summary
    • The metabolic syndrome is characterised by low-level inflammation, coagulation activation and increased risk of cancer. This study seeks to interrogate the inter-linked nature of these mechanisms in ovarian cancer. The association while present in ovarian cancer patients is not well defined. The aim of this study is to assess if platelet cloaking of CTCs in obese patients with ovarian cancer, due to increased systemic inflammation is a mechanism underlying worse prognosis in these patients.
  • Funding Agency
    • Royal City of Dublin Hospital Trust
  • Date From
    • 2013
  • Date To
    • 2016
  • Title
    • THE ROLE OF TISSUE FACTOR IN THE TRANSITION FROM ENDOMETRIOSIS TO CLEAR CELL CANCER OF THE OVARY
  • Summary
    • Increased expression of both PAR-2 and TF in the eutopic and ectopic endometrium from women with endometriosis compared with normal women has been reported (Krikun et al,2008) however it is unknown whether a further increase in expression is implicated in malignant transformation of endometrioma into clear cell cancer. Our hypothesis is that expression and activation of the TF-VIIa-PAR-2 signalling pathway is further increased in clear cell cancers particularly those formed on a background of endometriosis and that this may provide a potential target for treatment of clear cell cancers. We also believe that TFPI-2 may be a useful diagnostic marker for clear cell cancers. The aim of the study is to compare the expression of TF, VIIa and PAR-2 in clear cell cancers with endometrial tissue from patients with endometriosis. A secondary aim is to investigate the role of serum TFPI-2 as a possible non invasive tool for distinguishing endometriosis from clear cell cancers.
  • Funding Agency
    • Leo pharma
  • Date From
    • 2014
  • Date To
    • 2016
  • Title
    • Thromboelastography as a predictor of venous thrombosis in gynaecological oncology patients undergoing surgery.
  • Summary
    • Ovarian cancer is associated with high rates of venous thromboembolism (VTE) particularly after surgery even in the setting of appropriate prophylaxis.The treatment and prevention of VTE is challenging in these patients after major surgery, as pelvic surgery itself is also an additional high risk factor for VTE. Thromboelastography(TEG) is a technique which allows rapid global assessment of haemostatic/fibrinolytic function and has been proposed as a marker of hypercoagulability in a variety of clinical settings. The aim of this study is to determine the level of hypercoagulability using TEG in patients undergoing major gynaecological surgery for suspected cancer, and to determine the potential of TEG as a predictor of VTE.
  • Funding Agency
    • Gynaecological Cancer Fund, SJH
  • Date From
    • 2012
  • Date To
    • 2015
  • Title
    • Endogenous thrombin potential (ETP) and microparticle tissue factor(TF) activity as markers of venous thromboembolism in gynaecological cancer patients.
  • Summary
    • Increased Tissue Factor from tumour cells may cause an enhanced plasma procoagulant activity ultimately resulting in VTE. The majority of these patient would have major pelvic surgery as part of their treatment, with the risk of bleeding. Endogenous Thrombin Potential (ETP) assay is a new method which has shown potential as predictor of VTE risk. The aim of the study is to compare the procoagulant activity in plasma of patients with benign and malignant ovarian tumous using the ETP assay. and to compare the procoagulant activity levels in patients following neoadjuvant chemotherapy with those undergoing surgery for primary tumours
  • Funding Agency
    • Leo Pharma IIS/Gynaecological Oncology Fund SJH
  • Date From
    • 2010
  • Date To
    • 2013
  • Title
    • Prediction and Prevention of venous thromboembolism in pregnancy
  • Summary
    • Venous thromboembolism remains the leading cause of maternal morbidity and mortality. Delayed diagnosis, inadequate treatment and inadequate thromboprophylaxis account for the majority of deaths associated with this disease. Pharmacokinetics studies are required in specific groups of pregnant women receiving LMWH prophylaxis in order to devise effective evidence based dosing strategies. The recent triennial report indentified obese pregnant women and women post caesarean section, as two groups particularly at risk and where further work is required. This study will (1) investigate thrombin activity as a potential predictive tool for venous thromboembolism in pregnancy using the SCOPE study cohort (2) study the full anticoagulant (anti-IIa and anti-Xa) profile of obese pregnant woman and women post caesarean section receiving LMWH prophylaxis.
  • Funding Agency
    • Anu Research Fellowship/Leo Laboratories
  • Date From
    • July 2009
  • Date To
    • July 2012
  • Title
    • THE ROLE OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR IN OVARIAN CANCER
  • Summary
    • Tissue Factor (TF) is a potent trigger of the coagulation cascade which is normally released following vascular injury. In normal tissue, TF expression is restricted to extravascular sites however recent evidence has shown that tumour cells can constitutively express TF leading to thrombin and fibrin formation on the cell surface. This activation of the coagulation system has been shown to be related to survival and is also implicated in the increased venous thromboembolic (VTE) risk in cancer patients. Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signalling activities. TFPI exhibits anti-angiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumour associated TFPI have been shown to significantly reduce tumour cell induced activation and lung metastasis. Ovarian cancer is the leading cause of death from gynaecological malignancy. The lifetime risk of developing the disease is now estimated at 1 in 59. Ovarian cancer is known to display a particular association with VTE with reports of up to 14% of patients with clear cell carcinoma of the ovary developing thromboembolic complications. In addition, patients undergoing chemotherapy have an enhanced risk of vascular thrombosis which varies among different chemotherapeutic regimens. VTE is a life threatening condition and its management is challenging in these patients who often undergo major pelvic and abdominal surgery and receive combination chemotherapy. The pathological and cellular mechanisms underlying this thrombogenic risk in cancers are not fully understood. The aim of this study is to determine the role of TF and its inhibitor TFPI in the progression of ovarian cancer and to assess their potential as predictive tools for venous thrombosis in ovarian cancer patients during treatment.
  • Funding Agency
    • St. James's Hospital Gynae Oncology Fund
  • Date From
    • 2010
  • Date To
    • 2012
  • Title
    • Phytoestogens as an alternative to HRT: assessing thrombotic risk in cell and animal models
  • Summary
    • The aim of this study is to examine the molecular effects of phytoestrogens on the molecular determinants of thrombus formation in both cell and animal models. By understanding these effects we may be able to assess the potential of these compounds as oestrogen alternatives with less thrombotic risk.
  • Funding Agency
    • HRB
  • Date From
    • 2007
  • Date To
    • 2010
  • Title
    • An Investigation into the in vitro effects of oestradiol and norethisterone on coagulation and fibrinolytic gene expression
  • Summary
    • Although it is established that hormone preparations can alter coagulation and fibrinolytic activity, the mechanism for this and its relation to increased cardiovascular risk in hormone users is unclear. The aim of this study is to investigate the in vitro effects of estradiol and norethisterone on the expression of coagulation and fibrinolytic genes in cell culture. Using TaqMan PCR and low density arrays, the direct and indirect effects of these preparations will be investigated in endothelial and hepatocyte cultures
  • Funding Agency
    • TCD Obs and Gynae
  • Date From
    • 2008
  • Date To
    • 2011
  • Title
    • A comparative study of the effects of oral (estradiol 1mg/0.5mg norethisterone acetate) versus transdermal (estradiol 25µg/125µg norethisterone) on haemostatis in healthy post menopausal women
  • Summary
    • HRT is known to cause changes in coagulation and fibrinolytic gene activation which may explain the increased risk of thrombosis associated with these combinations. If these preparations are taken transdermally, the liver first pass effect is avoided and this may reduce their effects on coagulation and fibrinolytic activity. The aim of this study is to investigate the role of the route of admiminstration on the effects of HRT on haemostasis. Levels of coagulation and fibrinolytic activators and inhibitors will be measured in a group of healthy post menopausal women taking a transdermal preparation compared with a group taking an oral preparation
  • Funding Agency
    • Novartis
  • Date From
    • 2002
  • Date To
    • 2005
  • Title
    • Thrombomodulin and EPCR as novel therapeutics in type 1 ovarian cancers
  • Funding Agency
    • US Department of Defense

Keywords

Biomedical sciences; Cardiovascular risk assessment and hormone replacement therapy; Clinical research, trials; Coagulation biochemistry and disorders; Cytokines, Nitric Oxide; Foetal, maternal and neonatal physiology; Haemotology; Hormone physiology and biochemistry; Inflammation and coagulation syndromes; Medical Sciences, Research; Menopause; Molecular haematology; Oral contaraceptives and haemostasis; Pre-eclampsia and intrauterine growth retardation; Prevention, treatment of thromboembolic complications in pregnancy; Reproduction, fertility and contraception; Thrombosis and haemostasis; Vascular Biology, Thrombosis

Recognition

Representations

Co-Editor in Chief of Thrombosis Update 2019

Member of the Editorial board of Thrombosis Research

Member of International Society for Thrombosis and Haemostasis publications committee 2016-2020

Memberships

Member of International Society for Thrombosis and Haemostasis 2010 – 2020

Irish Society for Gynaecological Oncology 2016-present

Irish Association of Cancer Research 2015-present

Irish National Network for Ovarian Cancer Collaboration INNOVATION Founder member 2016 – Present